Switzerland-based GeNeuro SA has hired the neurologist David Leppert to be chief medical officer and manage development of its programmes for neurodegenerative and autoimmune diseases. Dr Leppert has expertise in multiple sclerosis and in an earlier role at Roche, led development of ocrelizumab. Subsequently, he joined Novartis where he led the development of all neurology clinical trials.
Dr Leppert is currently associate professor in neurology at the University of Basel, and will retain his academic appointment. He succeeds François Curtin who is leaving the company to join the Swiss Federal Institute of Technology in Zurich.
GeNeuro announced the appointment on 21 April 2020.
Copyright 2020 Evernow Publishing Ltd.